Microdialysis as a Tool in Local Pharmacodynamics

Submitted: August 23, 2005; Accepted: September 21, 2005; Published: April 7, 2006

YanJun Li,¹ Joanna Peris,² Li Zhong,³ and Hartmut Derendorf¹

¹Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL 32610

²Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL 32610

³Department of Pediatrics, College of Medicine, University of Florida, Gainesville, FL 32610

ABSTRACT

In many cases the clinical outcome of therapy needs to be determined by the drug concentration in the tissue compartment in which the pharmacological effect occurs rather than in the plasma. Microdialysis is an *in vivo* technique that allows direct measurement of unbound tissue concentrations and permits monitoring of the biochemical and physiological effects of drugs throughout the body. Microdialysis was first used in pharmacodynamic research to study neurotransmission, and this remains its most common application in the field. In this review, we give an overview of the principles, techniques, and applications of microdialysis in pharmacodynamic studies of local physiological events, including measurement of endogenous substances such as acetylcholine, catecholamines, serotonin, amino acids, peptides, glucose, lactate, glycerol, and hormones. Microdialysis coupled with systemic drug administration also permits the more intensive examination of the pharmacotherapeutic effect of drugs on extracellular levels of endogenous substances in peripheral compartments and blood. Selected examples of the physiological effects and mechanisms of action of drugs are also discussed, as are the advantages and limitations of this method. It is concluded that microdialysis is a reliable technique for the measurement of local events, which makes it an attractive tool for local pharmacodynamic research.

KEYWORDS: Microdialysis, pharmacodynamics (PD), neurotransmitter, glucose, hormone

INTRODUCTION

Microdialysis is a catheter-based sampling technique that provides the opportunity to sample analytes from the interstitial fluid in tissues to measure the free pharmacologically active concentration of exogenous or endogenous com-

pounds at a site closer to the target site than plasma.¹ The method has been used extensively in animal and human studies for decades.¹⁻⁵ Pharmacodynamics (PD) is the study of the biochemical and physiological effects of drugs on the body. In a more quantitative sense, it describes the relationship between drug concentration and effect. The effects of pharmacological agents on biochemical processes can be inferred using endogenous compounds as biological markers; for example, lactate is a marker for glycolysis and glycerol is an indicator of lipolysis.² Physiological effects are often the parameter used to indicate a local effect of a drug; for example, blood flow is decreased in the presence of norepinephrine and norepinephrine but increased in response to urapidil.⁶ Endogenous substances can also work as pharmacodynamic biomarkers to indicate the effects of drugs as well as further elucidate their mechanism of action in eliciting the physiological response.

Microdialysis requires sensitive analytical methods to measure low concentrations in small sample volumes. It is suitable for pharmacodynamic studies of complex interactions of drugs at their sites of action in intact living tissue, and it leaves endogenous metabolic and oxygenation pathways, as well as synaptic functions, largely intact.^{4,7} *In vivo* microdialysis allows the direct assessment of endogenous substances and is used in PD studies alongside, or instead of, other sampling techniques, such as equilibrium dialysis,⁸ ultrafiltration sampling,⁹⁻¹² saliva sampling,¹³⁻¹⁵ and skin blister fluid sampling.^{14,16} It has become an increasingly popular and powerful technique to determine extracellular concentrations of glucose, lactate, glycerol, hormones, and various neurotransmitters and/or their metabolites. This information is then used to assess the activities of various enzymes and the mechanisms of action of drugs.^{1-5,17-22}

MICRODIALYSIS

Principle of Microdialysis

Microdialysis is a sampling technique that is used to measure the concentration of the unbound fraction of endogenous and/or exogenous substances in the extracellular fluid of many tissues (eg, adipose tissue, brain, heart, lung, solid tumors).^{1,14,23} It is applicable to both animal and human studies. The basic principle is to mimic the function of a

Corresponding Author: Hartmut Derendorf, Department of Pharmaceutics, PO Box 100494, College of Pharmacy, University of Florida, Gainesville, FL 32610. Tel: (352) 846-2726; Fax: (352) 392-4447; E-mail: hartmut@cop.ufl.edu

capillary blood vessel by perfusing a thin dialysis probe with physiological fluid after it is inserted into the tissue of interest by means of a guide cannula. Continuous transfer of soluble molecules from the extracellular fluid into the probe occurs by means of a semipermeable membrane covering the tip of the probe. Samples are subsequently collected either (1) at intermittent time points for later analysis by standard chemical analytical techniques or (2) more recently, continuously for direct online analysis.¹

Features of Microdialysis

There are many advantages of microdialysis.^{1,14,24-27} It is a straightforward technique that is not too difficult to establish on a routine basis. Microdialysis sampling does not change the net fluid balance of the surrounding sample matrix and provides clean samples in which analytes are separated from further enzymatic action. Because there is no net fluid loss, samples can be collected continuously for hours or days from a single freely moving animal. Most important, each animal can serve as its own control, so microdialysis requires fewer subjects than do some other methods, such as direct tissue assay. It can be used in humans in a relatively noninvasive manner. Moreover, microdialysis is easily coupled with other chemical analysis, such as high-performance liquid chromatography (HPLC),^{27,28} mass spectrometry (MS),^{28,29} capillary electrophoresis (CE),^{30,31} and nuclear magnetic resonance (NMR).^{32,33} These techniques are often combined (eg, HPLC-MS,^{28,34} HPLC-NMR,^{33,35} HPLC-NMR-MS,³⁶⁻³⁸ CE-LIF (laser-induced fluorescence)³⁰) to enhance the specificity, sensitivity, reliability, and efficiency of separation and detection.

As with any technique, there are limitations in the application of microdialysis.²⁴⁻²⁷ Implantation of the probe almost certainly leads to tissue reactions that can interfere with the physiological system under investigation. To minimize this interference, optimal times after probe implantation must be determined specifically for the analyte of interest. For example, the optimal time to measure endogenous dopamine levels after probe insertion may differ from the optimal time to measure glutamate levels because of the continuing process of gliosis at the site of probe tissue damage. Another problem is that highly lipophilic drugs stick to tubing and probe components, complicating the relationship between dialysate and extracellular concentrations. Most important, microdialysis causes dilution of analyte levels in 2 ways. First, endogenous analyte levels may be decreased near the probe, leading to a tissue reaction and change in physiological status. Second, the diluting effect of the dialysis procedure leads to lower concentrations of analyte in samples compared with tissue, requiring both sensitive analytical methods and determination of *in vivo* recovery of the analyte to calculate true concentrations in the extracellular

fluid. This latter technique may impose temporal limitations (eg, the no-net-flux method may require hours of sampling) and may be confounded by physiological conditions that change over time.

MICRODIALYSIS AS A TOOL IN LOCAL PD

Analysis of Neurotransmitters Using Microdialysis

There are more than 300 known neurotransmitters, including acetylcholine, norepinephrine, dopamine, serotonin (5-HT), amino acids, peptides, adenosine triphosphate, and gases (eg, nitric oxide). Neurotransmitters convey information within the brain and from the brain to all parts of the body. Measuring the changes in neurotransmitter extracellular levels in discrete brain areas can help identify the neuronal systems involved in specific behavioral responses or cognitive processes.³⁹ In 1974, Ungerstedt and Pycock first described the use of an osmotic membrane in the recovery of neurotransmitters.⁴⁰ However, it was not until the 1980s that it became possible to analyze brain chemistry quantitatively. Analysis of neurotransmitters and related substances in the dialysates from probes inserted into discrete brain areas has been extensively used to monitor extracellular levels of neurotransmitters, yielding a great deal of information about functional interactions of endogenous neurotransmitter systems.⁴¹ Moreover, combined with either systemic or local delivery of drugs, microdialysis has been used to monitor drug-induced changes in neurotransmitters and other endogenous compounds, resulting in informative correlations between these levels and behavioral changes induced by psychotropic drugs, perhaps contributing to the elucidation of mechanisms of drug action. For example, interactions of biogenic amines with isozymes of monoamine oxidase, and interactions of biogenic amines and amino acids with each other, have been described using this technique.^{41,42}

Acetylcholine

Acetylcholine (ACh) is the first neurotransmitter whose diffusion from the central nervous system was investigated and whose extracellular levels were correlated to changes in neuronal activity. ACh can be detected in the extracellular fluid even in the absence of cholinesterase inhibitors. However, to facilitate ACh quantification and reduce the duration of sample collection, a cholinesterase inhibitor is commonly added to the dialysis solution.^{39,43} The dorsal striatum is a common target for early microdialysis studies because of its important role in locomotor and cognition function as well as its large size and easy accessibility to dialysis probes. Microdialysis has been used to demonstrate that dopamine directly inhibits striatal ACh release via D2 receptors in the striatum and indirectly stimulates ACh release via D1 receptors outside the striatum.²⁷ Since the

establishment of the microdialysis method in the striatum, pharmacological studies of ACh release in the terminal regions of the basal forebrain cholinergic system (BFCS)—the cortex, hippocampus, and amygdala—using microdialysis have become increasingly prevalent.²⁷

In 1988, Maysinger et al detected striatal and cortical extracellular ACh and choline levels in samples collected using microdialysis coupled with a sensitive HPLC technique in normal and decorticated rats treated with saline or the monoganglioside GM1.⁴⁴ Picomole amounts of ACh could be measured when the acetylcholinesterase inhibitor (neostigmine) was included in the microdialysis perfusion medium. Maysinger et al found that GM1 treatment increased the ability of cortical cholinergic terminals to release ACh, allowing the brain to promote recovery following injuries to the central nervous system.^{44,45} Watanabe and Shimizu found that the cholinergic antagonists atropine and scopolamine increased both striatal ACh release and motor activity, while the quaternary ammonium compounds atropine methylbromide and methscopolamine bromide increased striatal ACh release without motor excitation. These results demonstrated that anticholinergic drugs can cause an increase in striatal ACh release that does not always result in an increase in motor activity.⁴⁶ Since then, ACh release in the striatum has been shown to be stimulated by an orally active novel nicotinic agonist TC-1734,⁴⁷ an adenosine A2a receptor agonist,⁴⁸ N-methyl-D-aspartate (NMDA),⁴⁹ substance P,^{50,51} estradiol, raloxifene,⁵² the arousal-promoting peptide hypocretin,⁵³ and somatostatin⁵⁴; and inhibited by gamma aminobutyric acid A receptor agonists,⁵⁵ adenosine A1 receptor agonist,⁵⁶ neuropeptide galanin,⁵⁷ and the general anesthetic isoflurane,⁵⁸ allowing for a much better understanding of the regulation of locomotor activity by the basal ganglia.

In many cases, drug delivery via reverse microdialysis (inclusion of the drug in the perfusing medium) either to the cholinergic terminal region being sampled or to other brain regions has elucidated the possible sites of action involved in regulating ACh release.²⁷ For example, administration of an NMDA antagonist to the cortex via reverse dialysis has no effect on cortical ACh release, whereas delivery of the drug to the cell body region of the BFCS neurons decreases cortical ACh release.⁴³ On the other hand, local administration of an NMDA antagonist to the lateral septum emulates the effects of intracerebroventricular injection to increase cortical ACh release.⁵⁹ Similarly, microdialysis using multiple probe implantation sites can be used to determine the anatomy of a given pharmacological effect.⁵⁹⁻⁶²

Catecholamines

Microdialysis allows the in vivo measurement of catecholamines, such as epinephrine, norepinephrine (NE), and

dopamine (DA), aiding in the investigation of the mechanisms that underlie their local release and clearance as hormones and neurotransmitters. Zetterstrom et al⁶³ studied the effect of amphetamine on DA release and metabolism in 1983. Theirs was one of the first studies undertaken with the in vivo microdialysis technique. The microdialysis technique was used to compare the effect of amphetamine on the level of DA, NE, and their metabolites in the extracellular fluid of the striatum, nucleus accumbens (Nac), and lateral hypothalamus with alterations in behavior.^{64,65} In 1992, Okuda et al used microdialysis to demonstrate increases in extracellular striatal DA levels and locomotor activity after deprenyl administration with L-dopa for the treatment of Parkinson's disease.⁶⁶ It was shown that deprenyl and *l*-methamphetamine (*l*-MeAmp) were both present in striatal dialysate at 10 and 60 minutes, indicating that both the deprenyl and the metabolically generated *l*-MeAmp contribute to the DA response.⁶⁷

Recently, microdialysis has been used as a tool to measure extracellular DA and NE after atypical antipsychotic administration. Using in vivo microdialysis, Pira et al⁶⁸ found that quetiapine markedly increased extracellular levels of both NE and DA in the prefrontal cortex (Figure 1A and B) but had only a weak effect on DA levels in the caudate nucleus (Figure 1C). Quetiapine increased extracellular NE release in the caudate nucleus, as expected from its α_2 -adrenoceptor antagonist profile (Figure 1D). These findings might be related to the therapeutic action of quetiapine in schizophrenia and its low risk of inducing extrapyramidal side effects.

Stress-induced NE release in the medial amygdala, acting primarily through α_1 receptors, facilitates activation of the hypothalamic-pituitary-adrenal axis.⁶⁹ Kushikata et al⁷⁰ measured NE release by microdialysis in the preoptic area and the posterior hypothalamus before, during (30 minutes), and after (50 minutes) rats were anesthetized with isoflurane. They found that isoflurane increases NE release in these areas, suggesting that augmentation of NE release in the preoptic area is responsible for hypothermia during general anesthesia.

A large number of studies have focused on DA changes in the cell body and terminal regions of the mesolimbic and mesocortical pathways involved with drug reinforcement and addiction. Repeated use of cocaine produces behavioral sensitization that is associated with alterations in DA levels in the striatum,^{27,71,72} the Nac,⁷¹⁻⁷⁶ and the medial prefrontal cortex.^{27,71} Similarly, the different levels of morphine-induced locomotor hyperactivity found in 2 inbred mouse strains, DBA/2J and C57BL/6J, appear to be mediated by different sensitivity of both the dopaminergic and the serotonergic systems in the Nac and the dorsal striatum.⁷² Ethanol reinforcement and subsequent consumption has been shown, primarily via the use of the microdialysis technique, to be regulated by the degree of neuronal firing in the mesolimbic

Figure 1. Effect of quetiapine (5, 10, and 20 mg/kg intraperitoneally) on extracellular noradrenaline and dopamine concentrations in the prefrontal cortex (A and B) and in the caudate nucleus (C and D), measured by microdialysis. Data represent the mean values $\pm$ SEM of 4 to 6 rats. Statistical significance was calculated with a repeated-measures analysis of variance followed by a Dunnett test. Closed symbols indicate $P < .05$ with respect to basal values.⁶⁸

DA pathway. Initial exposure to low doses of ethanol increases mesolimbic DA transmission,^{73,74,76,77} and repeated ethanol exposure further activates DA transmission.⁷⁵ This enhancement may increase alcohol cravings and consumption, since animals in which DA efflux in the Nac is disrupted exhibit reduced alcohol preference.^{75,78} Ethanol-induced increases in DA also occur in the central nucleus of the amygdala, another region implicated in the formation of positive reinforcement associations,⁷⁷ whereas ethanol decreases DA efflux in striatal regions involved with motor function.⁷⁹ Finally, both naltrexone and acamprosate decrease ethanol self-administration behavior and ethanol-induced increases in DA in the Nac,^{75,80} indicating an interaction of these agents with DA mediation of positive reinforcement by ethanol.

Serotonin

Serotonin, or 5-hydroxytryptamine (5-HT), is found in the brain, serum, and gastric mucosal membranes. Its role as a neurotransmitter in diverse functions includes learning, sleep, and control of mood. The structural similarity of 5-HT to several drugs known to cause mental aberrations, such as lysergic acid diethylamide, has prompted much

speculation as to the role of 5-HT in naturally occurring mental disorders such as schizophrenia and depression.

The microdialysis technique has been widely used to monitor the release of 5-HT.^{64,72,81-89} In 1987, Hernandez et al⁹⁰ tested the effects of systemic and local amphetamine on 5-HT release in the Nac and ventral striatum in freely moving rats. Using microdialysis to measure cortical release of 5-HT in freely moving rats, Owen and Whitton suggested that combined treatment of clinically tolerated NMDA antagonists such as amantadine could reduce the delay in therapeutic onset of tricyclic antidepressants and selective 5-HT uptake inhibitors, as well as possibly enhance their efficacy.⁸⁹

The extracellular concentration of the 5-HT metabolite, 5-hydroxyindoleacetic acid (5-HIAA), is much higher than that of 5-HT. Therefore, the extracellular level of 5-HT, as monitored by the microdialysis technique, is closely related to serotonergic neuron activity, while the extracellular level of 5-HIAA has generally not been thought to be as directly related.⁹¹ However, similar percentage increases for both 5-HT and 5-HIAA dialysate levels were found in the guinea pig brain after 5-HT_{1B} autoreceptor blockade.^{92,93} These findings challenged the general opinion and indicate the need to reevaluate the relationship between extracellular 5-HIAA concentrations and 5-HT release.⁹¹

Amino Acids

Amino acids such as glutamate, aspartate, glycine, and gamma-aminobutyric acid (GABA) can serve as either excitatory or inhibitory neurotransmitters in the brain and spinal cord. Glutamate and aspartate are excitatory transmitters, and GABA and glycine are well-known inhibitory neurotransmitters. In 1986, microdialysis combined with HPLC was used to determine *in vivo* GABA release in the globus pallidus after a 6-hydroxydopamine lesion in the substantia nigra of the rat.⁹⁴ Since then, numerous studies have used microdialysis to indicate changes in basal or stimulated amino acid neurotransmitter levels during such diverse situations as severe insulin-induced hypoglycemia,⁹⁵ angiotensin antagonist-induced decreases in mean arterial pressure,⁹⁶ and subchronic administration of the DA D₁/D₂ agonist apomorphine after lesions of the substantia nigra pars reticulata.⁹⁷ Microdialysis has also been used to investigate the actions of antidepressant⁸⁷ and antiepileptic⁹⁸ drugs in specific brain regions.

Amino acid neurotransmission is also altered by the addiction process. For example, acute ethanol treatment increases taurine levels in the Nac, while repeated ethanol exposure further increases ethanol-stimulated taurine release.⁹⁹⁻¹⁰² Behavioral evidence suggests that taurine alters the reinforcing properties of ethanol,¹⁰³ possibly via modulation of DA transmission. Along these lines, genetically selected

lines of rats differing in ethanol self-administration behavior exhibit alterations in both ethanol-induced taurine and DA efflux in Nac.^{100,104-107} There is very little evidence that ethanol changes GABA, glycine, or glutamate levels in any brain region.^{99,101,102,104} Instead, increases in glutamate are caused by ethanol withdrawal.¹⁰⁷⁻¹¹¹ The use of microdialysis has not only elucidated these changes but also indicated a possible mechanism of action for the anti-alcohol craving drug acamprosate, since it has been shown to normalize glutamate levels after alcohol withdrawal.^{109,112,113}

One important caveat in using microdialysis to study extracellular levels of amino acids in the brain and infer alterations in neuronal function is that many amino acids are also important intermediates in energy and nitrogen metabolism in the brain. Therefore, the question of whether interstitial glutamate, GABA, taurine, and glycine levels measured using microdialysis represent synaptic activity is quite controversial.²⁻⁵ To clarify the origin of interstitial glutamate in the brain, Rooyackers has reviewed current studies on this issue.¹¹⁴ Many findings have suggested that extracellular glutamate mainly represents the neurotransmitter functions of glutamate, but conflicting conclusions have also been drawn.^{2,5,114} Current techniques for measurement of the release of these amino acids in vivo have been called into question¹¹⁵ as detecting extrasynaptic glutamate and GABA from only nonneuronal origins. Although it is conceivable that amino acids from a nonneuronal origin may alter neuronal signaling,¹¹⁶ it is imperative that a methodology be used with sufficient sensitivity to detect changes in amino acid content that reflect signaling and not only metabolic status. The use of a novel method to increase the sensitivity of detection of amino acids separated by CE has resulted in much higher temporal resolution for measuring extracellular levels of glutamate, GABA, taurine, and other amino acids.^{30,117} This technique enables detection of transient increases in these substances shown to be derived almost exclusively from neurogenic release.¹¹⁸ Thus, by using this methodology, changes in these amino acids associated with neuronal signaling can be distinguished from metabolic or osmotic events. Using stable isotope tracers in combination with microdialysis is expected to be useful for studying those issues in the human brain, helping to reveal more about the cause of the increased glutamate levels and about glutamate (in combination with glutamine) metabolism in the human brain in general.¹¹⁴ For example, a simple question of whether increased interstitial glutamate levels are caused by increased glutamate release or by decreased clearance by glial cells could be addressed by this method.¹¹⁴ An approach similar to this method has also been described to assess glucose kinetics in human muscle and adipose tissue, indicating that the fractional extraction of glucose tracers infused via microdialysis could be used as an index of glucose disposal in peripheral tissues or tissue beds.¹¹⁹

Peptides

Over 100 peptides, such as substance P, enkephalins, endorphin, vasopressin, oxytocin, vasoactive intestinal peptide, somatostatin, and adrenocorticotrophic hormone, have been identified as neurotransmitters. Microdialysis has been used to study the extracellular concentrations of peptides in response to various drugs over the past 15 years. The peptide content of the samples in microdialysates can be directly analyzed without further preparation because the size limit for the peptide molecules passing through the membrane is small, and for this reason the chance of enzymatic degradation of the dialysis sample is decreased. Therefore, it is not necessary to add inhibitors for preventing peptide degradation, and possible pharmacological effects induced by such inhibitors can be avoided.¹²⁰

In 1989, microdialysis combined with radioimmunoassay (RIA) was used to detect the release of neurokinin A-like immunoreactivity induced by amphetamine¹²¹ or acute and subchronic haloperidol treatment.¹²² Microdialysis was used to demonstrate the ability of typical (haloperidol) and atypical (risperidone) antipsychotic drugs to block amphetamine-stimulated neuropeptide Y levels in certain brain regions.¹²³ Landgraf et al used simultaneous microdialysis to monitor the release of vasopressin and oxytocin within the hypothalamic supraoptic and paraventricular nuclei and into the systemic circulation before and after central administration of interleukin-1 beta. The results indicated that the cytokine-induced central and peripheral release pattern appeared to be independent of the rise in body temperature.¹²⁴ In vivo microdialysis studies were also performed to examine the role of somatostatin receptors (sst₁) in controlling somatostatin release.¹²⁵

Beta-endorphin is an endogenous opioid that is released in the cell body and terminal regions of the mesolimbic pathway by cocaine, amphetamine, and ethanol.¹²⁶⁻¹²⁸ Solinas et al¹²⁹ used microdialysis while rats performed a 2-lever choice discrimination procedure for delta-9-tetrahydrocannabinol (THC) to investigate whether THC-induced changes in endogenous levels of beta-endorphin regulate the discriminative effects of THC. They showed that THC produces large increases in extracellular levels of beta-endorphin in the cell body region (ventral tegmental area) and lesser increases in the terminals present in the shell of the Nac.

Cholecystokinin (CCK) is a peptide hormone of the gastrointestinal system responsible for stimulating the digestion of fat and protein, but it is also an abundant neurotransmitter in the brain. It is colocalized with DA, is known to modulate DA neurotransmission, and is involved in behavioral sensitization to psychostimulants. To better understand its role, CCK was measured by microdialysis in the Nac in response to cocaine in drug-naïve and cocaine-sensitized rats. In cocaine-sensitized rats, cocaine-induced increases

in CCK levels were significantly higher than in drug-naïve animals. These results provide evidence for an activation of the mesolimbic CCK system in response to repeated cocaine administration.¹³⁰

Immunoassay, particularly RIA, is the approach most commonly used to analyze neuropeptides in dialysate.¹²¹⁻¹²⁴ However, because of the potential for cross-reactivity with peptides that contain similar epitopes, great care must be taken in applying RIA. Other techniques such as capillary liquid chromatography (LC) with electrochemical detection and capillary LC coupled with tandem MS have been used for determination of peptides *in vivo*.^{29,131,132} Recently, Baseski et al²⁹ used *in vivo* microdialysis sampling coupled with capillary LC/electrospray ionization quadrupole ion trap MS to monitor [met]enkephalin and [leu]enkephalin in the striatum of anesthetized and freely moving rats. The method was successfully used to monitor these peptides under basal conditions and after stimulation by elevated K⁺ concentration (Figure 2).²⁹ Microdialysis combined with other *in vivo* techniques has provided new insights into the secretory capacity of peptidergic neurons of the mammalian brain and has gained attention as a tool for direct monitoring of peptide neurotransmitters.

Other Neurotransmitters

Purines (adenosine triphosphate [ATP] and guanosine triphosphate [GTP], and their derivatives), a pyrimidine ring fused to an imidazole ring, are generally considered to be neurotransmitters in autonomic neurons. In 1991, Sijbesma et al examined the effects of intraperitoneal (IP) administration of 8-hydroxy-2-(di-n-propylamino) tetralin on the

efflux of cyclic adenosine monophosphate in the extracellular fluid of the dorsal hippocampus, using *in vivo* microdialysis.¹³³ Implanting microdialysis probes into the renal cortex and measuring adenosine and inosine levels in the dialysate exiting the kidney, the researchers documented that 3-isobutyl-1-methylxanthine, a phosphodiesterase inhibitor, decreases renal cortical interstitial levels of adenosine and inosine.¹³⁴ Reverse dialysis of adenosine is capable of raising extracellular kynurenic acid in the rat striatum by interacting with postsynaptic neuronal A1 receptors.¹³⁵

Anandamide and arachidonyl ethanolamine, also known as AEA, are naturally occurring endogenous cannabinoids that are thought to act as neurotransmitters. Giuffrida et al¹³⁶ found that anandamide release was increased 8-fold over baseline in the dorsal striatum of freely moving rats after local administration of the D2-like (D2, D3, D4) DA receptor agonist quinpirole, and this response was prevented by the D2-like receptor antagonist raclopride. These results suggest that functional interactions between endocannabinoid and dopaminergic systems may contribute to striatal signaling.

Nitric oxide (NO) and carbon monoxide (CO), both gases, can serve as signaling molecules between nerve cells. The NO level in a sample can be assayed by measuring the NO metabolites (NO₂⁻ and NO₃⁻) using an automated NO detector-HPLC system.^{137,138} In brief, a dialysate sample (20 µL) was collected into the sample loop of the automatic sample injector. NO₂⁻ and NO₃⁻ were separated on a packed column, and NO₃⁻ was reduced to NO₂⁻ in a cadmium reduction column. NO₂⁻ was mixed with Griess reagent in a reaction coil and measured using a UV detector at 540 nm.^{137,138} The effect of erythropoietin on NO production in the rat hippocampus revealed that NO levels gradually increased after the injection of erythropoietin. The increase in NOx levels was blunted by nicardipine, a Ca²⁺ channel blocker, but not by MK-801, an antagonist of NMDA receptors. These findings suggest that erythropoietin increased NO production in the rat hippocampus by activating voltage-gated Ca²⁺ channels but not through NMDA receptors.¹³⁷ Hara et al examined the effect of CO poisoning on the NO system in the striatum of freely moving rats using *in vivo* brain microdialysis. The investigators found that the extracellular levels of the oxidative NO products decreased during exposure to CO at a condition that causes CO poisoning. The findings suggest that CO poisoning suppresses NO production in rat striatum *in vivo* though a mechanism that may be different from that of hypoxia.¹³⁸

Figure 2. ME and LE levels resulting from perfusion of artificial cerebral spinal fluid through microdialysis probe with increasing concentrations of K⁺ for 15 minutes into an anesthetized rat. Values are reported as a percentage of basal level. Basal levels were determined as the average of 2 to 5 assays collected prior to stimulation in each animal. Error bars represent ± 1 SEM. ME indicates [met]enkephalin; LE, [leu]enkephalin.²⁹

Analysis of Glucose, Lactate, Glycerol, and Local Blood Flow Using Microdialysis

Glucose is the primary fuel used by most cells in the body to generate the energy that is needed to carry out cellular

functions. In animals, glucose can be formed in the liver and skeletal muscle by the breakdown of glycogen stores or synthesized in the liver and kidneys from intermediates by a process known as gluconeogenesis. Lactate is a 3-carbon compound that is produced when insufficient oxygen is present in cells to break down pyruvate to acetyl CoA. Measures of glucose, lactate, and glycerol in peripheral and central tissues by microdialysis can be useful as biological markers for glycolysis and lipolysis.^{22,139-143} Microdialysis allows studies on several tissues¹³⁹ or several regions of the same tissue at the same time^{22,142,143} as well as allowing simultaneous measurement of glucose, lactate, and glycerol.^{142,143}

In vivo microdialysis has been used to monitor the effect of different substances on glucose uptake in different tissues, including skeletal muscle,^{139,140,143,144} adipose tissue,^{22,139,144,145} and the brain.^{141,142} The technique was used to examine increases in glucose levels in the rat hippocampus during pentobarbital (45 mg/kg) or ketamine-xylazine (66 mg/kg, 7 mg/kg) anesthesia. The glucose levels of the extracellular fluid of the hippocampus were found to increase during anesthesia, supporting the view that extracellular fluid glucose levels in the hippocampus are dynamically coupled to local neural activity.¹⁴¹ Microdialysis catheters were placed in the brain to measure interstitial concentrations of glucose, lactate, and glycerol at the same time after IV infusion of low-dose prostacyclin in an experimental model of vasogenic brain edema of piglets. Prostacyclin caused a decrease in glucose, an increase in lactate, an increase in the lactate/glucose ratio, and an increase in glycerol.¹⁴² In another study, microdialysis was used to determine interstitial glucose concentrations in abdominal subcutaneous adipose tissue after the tissue was stimulated with the α_1 -agonist norfenefrine, the $\alpha_{1,2}\beta$ -agonist NE, and the α_1 -antagonist urapidil in 24 severely obese human subjects. Both norfenefrine and NE caused a concentration-dependent decrease in interstitial glucose concentration. Preperfusion of adipose tissue with urapidil inhibited this decrease and enhanced extracellular glucose at high concentrations.²²

Microdialysis has been successfully used in human subjects to monitor glucose levels in various peripheral tissues.^{17,22,23,143} In Hamrin and Henriksson's study,¹⁴³ the local effect of the insulin-mimetic agent vanadate on glucose metabolism in human skeletal muscle was investigated using in vivo microdialysis. Reverse dialysis with vanadate dose dependently decreased interstitial glucose concentrations, most likely secondary to an increased cellular glucose uptake. The accompanying dose-dependent increase in lactate reflected the increased glucose uptake, which stimulates muscle glucose metabolism and lactate formation. The effect of in vivo insulin-stimulated glucose utilization in relation to glycolysis (lactate formation) in peripheral tis-

sues was investigated. The results indicated that vanadate mimics the effect of insulin in human skeletal muscle in vivo.

Microdialysis was also used to measure the blood flow and/or glucose levels in tissues such as in skeletal muscle and adipose tissue after drug treatment.^{22,144,146} In Flechtner-Mors et al's studies,²² 4 microdialysis probes were implanted in abdominal subcutaneous adipose tissue, and 3 of the probes were used to determine the effects on changes in interstitial glucose concentration and blood flow of the α_1 -agonist norfenefrine, the $\alpha_{1,2}\beta$ -agonist NE, and the α_1 -antagonist urapidil, respectively, in a single concentration over time. The fourth microdialysis probe was implanted in all of the subjects to measure basal glucose concentration during the study period. Orciprenaline decreased adipose tissue glucose concentrations as well as increased nutritive blood flow. Local adipose blood flow decreased in the presence of norfenefrine and NE but increased in response to urapidil. The accelerated blood flow due to urapidil was counteracted by NE and norfenefrine. The observed changes in local adipose blood flow induced by adrenergic agents were not related to glucose uptake.²² Djurhuus et al¹⁴⁴ assessed skeletal muscle blood flow using plethysmography applied to the thigh contralateral to the microdialysis probes. A cuff was inflated to 300 mmHg at the level of the patella to measure flow exclusively in the thigh. Djurhuus et al also assessed the impact of similar growth hormone (GH) and cortisol exposures on adipose tissue blood flow with the ¹³³Xe washout technique.^{144,146} In brief, approximately 3 MBq of ¹³³Xe was injected into the subcutaneous adipose tissue of the abdomen ~5 cm sinistrolateral to the umbilicus. Disappearance of ¹³³Xe was continuously measured starting from 30 minutes after injection by use of an NaI detector.¹⁴⁶ The results indicated that coadministration of GH and cortisol does not influence adipose tissue blood flow.¹⁴⁴

One of the most exciting clinical applications of microdialysis is its use in measuring glucose in diabetic patients. Recently, a portable glucose sensor was developed for diabetic patients (Figure 3) under insulin treatment or with an artificial pancreas, providing improved metabolic control that delays or prevents the development of the long-term complications of these treatments.^{20,147,148} Reliable continuous glucose monitoring can provide more detailed information on postprandial glucose fluctuations than can single spot measurements, allowing feedback-controlled insulin delivery.^{1,17,18,20} In Freckmann et al's studies, continuous glucose monitoring of type 1 diabetic patients administered 3 daily 60-g carbohydrate meals resulted in glucose concentrations (140 ± 13 mg/dL) close to the target value of 120 mg/dL as well as stable levels during the night (Figure 4).²⁰ Continuous microdialysis sampling does not withdraw body fluid, so there are no factors limiting the amount of samples that can be taken from patients. There is only minimal

Figure 3. Schematic diagram of the continuous glucose monitoring system. The combination of microdialysis and enzymatic amperometric glucose measurement implemented in this device marked a breakthrough in achieving reliable and precise continuous tissue glucose monitoring. GOD indicates glucose oxidase.²⁰

perturbation of the system under study, making this technique more and more popular in preclinical and clinical studies.

Analysis of Hormones Using Microdialysis

Hormone molecules are secreted directly into the bloodstream, other body fluids, or adjacent tissues and serve as a signal to the target cells. Melatonin helps regulate circadian rhythms, presumably because its secretion is regulated by the circadian pacemaker in the suprachiasmatic nucleus. Nakahara et al established a system that enables long-term monitoring of melatonin secretion by implanting a trans-

verse microdialysis probe in or near the pineal gland in a freely moving mouse. Two daily peaks of secretion were observed, with the first, small peak at dusk and the second, large peak at midnight. The large nighttime peak was suppressed by tetrodotoxin, an Na⁺ channel blocker, and enhanced by both phenylephrine and isoproterenol, which are α - and β -adrenergic agonists respectively, whereas daytime melatonin levels were not affected by tetrodotoxin infusion.¹⁴⁹ Prolongation of NE-stimulated melatonin release was observed after reverse dialysis of the β -adrenergic and α -adrenergic receptor agonists into the pineal gland.¹⁵⁰

Vascular endothelial growth factor (VEGF) is a peptide hormone and considered a key mediator of tumor angiogenesis, including neovascularization in human breast cancer cells. Microdialysis was used to sample the extracellular space where VEGF is biologically active.^{151,152} Garvin and Dabrosin¹⁵² concluded that tamoxifen decreased extracellular VEGF in vivo in solid MCF-7 tumors in nude mice and illustrated that microdialysis is a viable method that may be applied in human breast tissue to detect soluble VEGF in situ released by the tumor.

Cortisol is an important steroid hormone secreted by the cortex of the adrenal glands. In vivo microdialysis was used to measure the conversion of cortisone to cortisol in abdominal subcutaneous adipose tissue before and after carbenoxolone was used to inhibit metabolic conversion. Human obese subjects showed more rapid initial conversion of [³H]cortisone to [³H]cortisol than did lean subjects. Conversion in both lean and obese groups plateaued at a similar level after 3 hours. After the introduction of hyperinsulinemia by insulin infusion, there was a rapid, temporary fall in cortisol generation in lean subjects but no change in obese subjects. There was not significant conversion of

Figure 4. Continuous glucose monitoring with the comparative microdialysis technique in a type 1 diabetic patient with glucose-controlled subcutaneous insulin infusion over 24 hours. □ stands for venous blood glucose and — for tissue glucose (comparative microdialysis technique). Insulin doses are represented by vertical bars. c.h. indicates carbohydrates.²⁰

[^3H]cortisone to [^3H]cortisol after carbenoxolone, indicating that carbenoxolone did not reduce 11β -hydroxysteroid dehydrogenase type 1 activity in regenerating cortisol from cortisone within adipose tissue in obese men as compared with lean men (Figure 5).¹⁵³ Thus, microdialysis allows measurement of small local changes in human subjects that many other techniques cannot provide.^{1,14,153}

Many times, the temporal pattern of release is an integral part of hormonal signaling, making the repeated measurement afforded by microdialysis indispensable.^{58,64,154,155} To study pulsatile secretion of hypothalamic gonadotropin-releasing hormone (GnRH), the effects of arcuate nucleus-median eminence (AME) administration of desipramine (a specific NE transporter blocking drug) on GnRH release were examined. First, 0.2- to 10-mM doses of desipramine were delivered continuously for 1 hour via AME reverse dialysis into intact male rabbits. Desipramine stimulated a GnRH pulse, and the size of the GnRH pulse was proportional to the

dosage of desipramine. Simultaneous determination of the catecholamine content of microdialysis samples confirmed the specificity of desipramine for NE transport.¹⁵⁴

CONCLUSIONS AND PERSPECTIVES

Most drugs exert their pharmacologic effects on extravascular structures rather than in the bloodstream. Thus, the interstitial fluid of a target tissue may be regarded as the true anatomical “effect compartment.” Therefore, the local tissue levels of endogenous compounds can be a very important biological marker used to determine the drug concentration versus drug effect profile. Microdialysis allows direct assessment of endogenous substances in multiple sites and continuous sampling in the same individual and the same area with minimal tissue perturbation and high sensitivity in small sample volumes. Elegant separation methods are available. These features make microdialysis a very efficient diagnostic tool for local pharmacodynamic studies, both peripherally and centrally. The present examples are not meant to be exhaustive but to illustrate the application of microdialysis for measuring the effect of the drug on extracellular levels of endogenous substances in peripheral compartments. In addition, microdialysis has contributed greatly to the understanding of hormone signaling and the interactions between drugs and neurotransmitters in the nervous system. It can be expected that this technique will be further refined to afford even more brain region and cellular specificity as well as more detailed analysis of peptide, fatty acid, and gaseous signaling compounds. This information will also provide a gateway to the development of more selective and effective psychotropic drugs in the future.

REFERENCES

1. Muller M. Science, medicine, and the future: microdialysis. *BMJ*. 2002;324:588-591.
2. de la Pena A, Liu P, Derendorf H. Microdialysis in peripheral tissues. *Adv Drug Deliv Rev*. 2000;45:189-216.
3. Yokoyama M, Suzuki E, Sato T, et al. Amygdalic levels of dopamine and serotonin rise upon exposure to conditioned fear stress without elevation of glutamate. *Neurosci Lett*. 2005;379:37-41.
4. Humpel C, Ebendal T, Olson L. Microdialysis: a way to study in vivo release of neurotrophic bioactivity: a critical summary. *J Mol Med*. 1996;74:523-526.
5. Tsai TH. Assaying protein unbound drugs using microdialysis techniques. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2003;797:161-173.
6. Flechtner-Mors M, Jenkinson CP, Alt A, et al. Sympathetic regulation of glucose uptake by the $\alpha 1$ -adrenoceptor in human obesity. *Obes Res*. 2004;12:612-620.
7. Johansen MJ, Newman RA, Madden T. The use of microdialysis in pharmacokinetics and pharmacodynamics. *Pharmacotherapy*. 1997;17:464-481.

Figure 5. In vivo microdialysis measurement of subcutaneous adipose 11HSD1 activity with and without hyperinsulinemia. Data are mean $\pm$ SE for 6 subjects per group for the conversion of [^3H]cortisone to [^3H]cortisol (microdialysis; upper panel) and plasma insulin levels (lower panel). For microdialysis, comparison of lean and obese subjects was performed by repeated-measures ANOVA. The changes with time of perfusion ($P < .001$) showed a highly significant interaction by group ($P < .002$ lean vs obese). Post hoc testing by Student's t tests showed significant differences in the first hour after cannula insertion ($*P < .02$) and in the first hour after introducing hyperinsulinemia ($*P < .002$). For microdialysis, the effect of CBX was determined by repeated-measures ANOVA of the difference between placebo and CBX; analysis at each time point revealed no effect of CBX ($P = .64$). ANOVA indicates analysis of variance; CBX, carbenoxolone.¹⁵³

8. Banker MJ, Clark TH, Williams JA. Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. *J Pharm Sci*. 2003;92:967-974.
9. Linhares MC, Kissinger PT. Pharmacokinetic monitoring in subcutaneous tissue using in vivo capillary ultrafiltration probes. *Pharm Res*. 1993;10:598-602.
10. Janle EM, Kissinger PT. Microdialysis and ultrafiltration. *Adv Food Nutr Res*. 1996;40:183-196.
11. Garrison KE, Pasas SA, Cooper JD, et al. A review of membrane sampling from biological tissues with applications in pharmacokinetics, metabolism and pharmacodynamics. *Eur J Pharm Sci*. 2002;17:1-12.
12. Leegsma-Vogt G, Janle E, Ash SR, et al. Utilization of in vivo ultrafiltration in biomedical research and clinical applications. *Life Sci*. 2003;73:2005-2018.
13. Major CJ, Read SE, Coates RA, et al. Comparison of saliva and blood for human immunodeficiency virus prevalence testing. *J Infect Dis*. 1991;163:699-702.
14. Muller M, Brunner M, Schmid R, et al. Comparison of three different experimental methods for the assessment of peripheral compartment pharmacokinetics in humans. *Life Sci*. 1998;62:PL227-PL234.
15. Hofman LF. Human saliva as a diagnostic specimen. *J Nutr*. 2001;131:1621S-1625S.
16. Borg N, Gotharson E, Benfeldt E, Groth L, Stahle L. Distribution to the skin of penciclovir after oral famciclovir administration in healthy volunteers: comparison of the suction blister technique and cutaneous microdialysis. *Acta Derm Venereol*. 1999;79:274-277.
17. Keck FS, Kerner W, Meyerhoff C, et al. Combination of microdialysis and glucosensor permits continuous (on line) SC glucose monitoring in a patient operated device, I: in vitro evaluation. *Horm Metab Res*. 1991;23:617-618.
18. Keck FS, Meyerhoff C, Kerner W, et al. Combination of microdialysis and glucosensor permits continuous (on line) SC glucose monitoring in a patient operated device, II: evaluation in animals. *Horm Metab Res*. 1992;24:492-493.
19. Bolinder J, Ungerstedt U, Arner P. Long-term continuous glucose monitoring with microdialysis in ambulatory insulin-dependent diabetic patients. *Lancet*. 1993;342:1080-1085.
20. Freckmann G, Kalatz B, Pfeiffer B, et al. Recent advances in continuous glucose monitoring. *Exp Clin Endocrinol Diabetes*. 2001;109:S347-S357.
21. Liu P, Muller M, Derendorf H. Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. *Int J Antimicrob Agents*. 2002;19:285-290.
22. Flechtner-Mors M, Jenkinson CP, Alt A, et al. Sympathetic regulation of glucose uptake by the alpha1-adrenoceptor in human obesity. *Obes Res*. 2004;12:612-620.
23. Muller M. Microdialysis in clinical drug delivery studies. *Adv Drug Deliv Rev*. 2000;45:255-269.
24. Hansen DK, Davies MI, Lunte SM, et al. Pharmacokinetic and metabolism studies using microdialysis sampling. *J Pharm Sci*. 1999;88:14-27.
25. de Lange EC, de Boer AG, Breimer DD. Methodological issues in microdialysis sampling for pharmacokinetic studies. *Adv Drug Deliv Rev*. 2000;45:125-148.
26. Parent M, Bush D, Rauw G, et al. Analysis of amino acids and catecholamines, 5-hydroxytryptamine and their metabolites in brain areas in the rat using in vivo microdialysis. *Methods*. 2001;23:11-20.
27. Day JC, Kornecook TJ, Quirion R. Application of in vivo microdialysis to the study of cholinergic systems. *Methods*. 2001;23:21-39.
28. Hows ME, Lacroix L, Heidbreder C, et al. High-performance liquid chromatography/tandem mass spectrometric assay for the simultaneous measurement of dopamine, norepinephrine, 5-hydroxytryptamine and cocaine in biological samples. *J Neurosci Methods*. 2004;138:123-132.
29. Baseski HM, Watson CJ, Cellar NA, et al. Capillary liquid chromatography with MS3 for the determination of enkephalins in microdialysis samples from the striatum of anesthetized and freely-moving rats. *J Mass Spectrom*. 2005;40:146-153.
30. Bowser MT, Kennedy RT. In vivo monitoring of amine neurotransmitters using microdialysis with on-line capillary electrophoresis. *Electrophoresis*. 2001;22:3668-3676.
31. Huynh BH, Fogarty BA, Martin RS, et al. On-line coupling of microdialysis sampling with microchip-based capillary electrophoresis. *Anal Chem*. 2004;76:6440-6447.
32. Kanamori K, Ross BD. Suppression of glial glutamine release to the extracellular fluid studied in vivo by NMR and microdialysis in hyperammonemic rat brain. *J Neurochem*. 2005;94:74-85.
33. Lucas LH, Wilson SF, Lunte CE, et al. Concentration profiling in rat tissue by high-resolution magic-angle spinning NMR spectroscopy: investigation of a model drug. *Anal Chem*. 2005;77:2978-2984.
34. Mayer BX, Namiranian K, Dehghanyar P, et al. Comparison of UV and tandem mass spectrometric detection for the high-performance liquid chromatographic determination of diclofenac in microdialysis samples. *J Pharm Biomed Anal*. 2003;33:745-754.
35. Kanamori K, Kondrat RW, Ross BD. ¹³C enrichment of extracellular neurotransmitter glutamate in rat brain: combined mass spectrometry and NMR studies of neurotransmitter turnover and uptake into glia in vivo. *Cell Mol Biol (Noisy-le-grand)*. 2003;49:819-836.
36. Lindon JC. HPLC-NMR-MS: past, present and future. *Drug Discov Today*. 2003;8:1021-1022.
37. Lindon JC, Nicholson JK, Wilson ID. Directly coupled HPLC-NMR and HPLC-NMR-MS in pharmaceutical research and development. *J Chromatogr B Biomed Sci Appl*. 2000;748:233-258.
38. Lommen A, Godejohann M, Venema DP, et al. Application of directly coupled HPLC-NMR-MS to the identification and confirmation of quercetin glycosides and phloretin glycosides in apple peel. *Anal Chem*. 2000;72:1793-1797.
39. Pepeu G, Giovannini MG. Changes in acetylcholine extracellular levels during cognitive processes. *Learn Mem*. 2004;11:21-27.
40. Ungerstedt U, Pycock C. Functional correlates of dopamine neurotransmission. *Bull Schweiz Akad Med Wiss*. 1974;30:44-55.
41. Bourne JA. Intracerebral microdialysis: 30 years as a tool for the neuroscientist. *Clin Exp Pharmacol Physiol*. 2003;30:16-24.
42. Khan SH, Shuaib A. The technique of intracerebral microdialysis. *Methods*. 2001;23:3-9.
43. Giovannini MG, Bartolini L, Kopf SR, et al. Acetylcholine release from the frontal cortex during exploratory activity. *Brain Res*. 1998;784:218-227.
44. Maysinger D, Herrera-Marschitz M, Carlsson A, et al. Striatal and cortical acetylcholine release in vivo in rats with unilateral decortication: effects of treatment with monosialoganglioside GM1. *Brain Res*. 1988;461:355-360.
45. Redmond JM, Gillinov AM, Blue ME, et al. The monosialoganglioside, GM1, reduces neurologic injury associated with hypothermic circulatory arrest. *Surgery*. 1993;114:324-332.

46. Watanabe H, Shimizu H. Effect of anticholinergic drugs on striatal acetylcholine release and motor activity in freely moving rats studied by brain microdialysis. *Jpn J Pharmacol*. 1989;51:75-82.
47. Gatto GJ, Bohme GA, Caldwell WS, et al. TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects. *CNS Drug Rev*. 2004;10:147-166.
48. Kurokawa M, Koga K, Kase H, et al. Adenosine A2a receptor-mediated modulation of striatal acetylcholine release in vivo. *J Neurochem*. 1996;66:1882-1888.
49. Buchholzer ML, Klein J. NMDA-induced acetylcholine release in mouse striatum: role of NO synthase isoforms. *J Neurochem*. 2002;82:1558-1560.
50. Kart E, Jocham G, Muller CP, et al. Neurokinin-1 receptor antagonism by SR140333: enhanced in vivo ACh in the hippocampus and promesthetic post-trial effects. *Peptides*. 2004;25:1959-1969.
51. De Souza Silva MA, Hasenohrl RU, Tomaz C, et al. Differential modulation of frontal cortex acetylcholine by injection of substance P into the nucleus basalis magnocellularis region in the freely-moving vs. the anesthetized preparation. *Synapse*. 2000;38:243-253.
52. Gibbs RB, Gabor R, Cox T, et al. Effects of raloxifene and estradiol on hippocampal acetylcholine release and spatial learning in the rat. *Psychoneuroendocrinology*. 2004;29:741-748.
53. Bernard R, Lydic R, Baghdoyan HA. Hypocretin-1 causes G protein activation and increases ACh release in rat pons. *Eur J Neurosci*. 2003;18:1775-1785.
54. Rakovska A, Kiss JP, Raichev P, et al. Somatostatin stimulates striatal acetylcholine release by glutamatergic receptors: an in vivo microdialysis study. *Neurochem Int*. 2002;40:269-275.
55. Vazquez J, Baghdoyan HA. GABAA receptors inhibit acetylcholine release in cat pontine reticular formation: implications for REM sleep regulation. *J Neurophysiol*. 2004;92:2198-2206.
56. Tanase D, Baghdoyan HA, Lydic R. Dialysis delivery of an adenosine A1 receptor agonist to the pontine reticular formation decreases acetylcholine release and increases anesthesia recovery time. *Anesthesiology*. 2003;98:912-920.
57. Elvander E, Schott PA, Sandin J, et al. Intraseptal muscarinic ligands and galanin: influence on hippocampal acetylcholine and cognition. *Neuroscience*. 2004;126:541-557.
58. Jansson A, Olin K, Yoshitake T, et al. Effects of isoflurane on prefrontal acetylcholine release and hypothalamic Fos response in young adult and aged rats. *Exp Neurol*. 2004;190:535-543.
59. Giovannini MG, Giovannelli L, Bianchi L, et al. Glutamatergic modulation of cortical acetylcholine release in the rat: a combined in vivo microdialysis, retrograde tracing and immunohistochemical study. *Eur J Neurosci*. 1997;9:1678-1689.
60. Yamamuro Y, Hori K, Tanaka J, et al. Septo-hippocampal cholinergic system under the discrimination learning task in the rat: a microdialysis study with the dual-probe approach. *Brain Res*. 1995;684:1-7.
61. Moor E, Schirm E, Jacso J, et al. Involvement of medial septal glutamate and GABAA receptors in behaviour-induced acetylcholine release in the hippocampus: a dual probe microdialysis study. *Brain Res*. 1998;789:1-8.
62. Arnold HM, Nelson CL, Neigh GN, et al. Systemic and intra-accumbens administration of amphetamine differentially affects cortical acetylcholine release. *Neuroscience*. 2000;96:675-685.
63. Zetterstrom T, Sharp T, Marsden CA, et al. In vivo measurement of dopamine and its metabolites by intracerebral dialysis: changes after d-amphetamine. *J Neurochem*. 1983;41:1769-1773.
64. Sharp T, Zetterstrom T, Ljungberg T, et al. A direct comparison of amphetamine-induced behaviours and regional brain dopamine release in the rat using intracerebral dialysis. *Brain Res*. 1987;401:322-330.
65. Parada M, Hernandez L, Schwartz D, et al. Hypothalamic infusion of amphetamine increases serotonin, dopamine and norepinephrine. *Physiol Behav*. 1988;44:607-610.
66. Okuda C, Segal DS, Kuczenski R. Deprenyl alters behavior and caudate dopamine through an amphetamine-like action. *Pharmacol Biochem Behav*. 1992;43:1075-1080.
67. Melega WP, Cho AK, Schmitz D, et al. l-methamphetamine pharmacokinetics and pharmacodynamics for assessment of in vivo deprenyl-derived l-methamphetamine. *J Pharmacol Exp Ther*. 1999;288:752-758.
68. Pira L, Mongeau R, Pani L. The atypical antipsychotic quetiapine increases both noradrenaline and dopamine release in the rat prefrontal cortex. *Eur J Pharmacol*. 2004;504:61-64.
69. Ma S, Morilak DA. Norepinephrine release in medial amygdala facilitates activation of the hypothalamic-pituitary-adrenal axis in response to acute immobilisation stress. *J Neuroendocrinol*. 2005;17:22-28.
70. Kushikata T, Hirota K, Kotani N, et al. Isoflurane increases norepinephrine release in the rat preoptic area and the posterior hypothalamus in vivo and in vitro: relevance to thermoregulation during anesthesia. *Neuroscience*. 2005;131:79-86.
71. Williams JM, Steketee JD. Time-dependent effects of repeated cocaine administration on dopamine transmission in the medial prefrontal cortex. *Neuropharmacology*. 2005;48:51-61.
72. Fadda P, Scherma M, Fresu A, et al. Dopamine and serotonin release in dorsal striatum and nucleus accumbens is differentially modulated by morphine in DBA/2J and C57BL/6J mice. *Synapse*. 2005;56:29-38.
73. Yoshimoto K, McBride WJ, Lumeng L, et al. Alcohol stimulates the release of dopamine and serotonin in the nucleus accumbens. *Alcohol*. 1992;9:17-22.
74. Yim HJ, Schallert T, Randall PK, et al. Comparison of local and systemic ethanol effects on extracellular dopamine concentration in rat nucleus accumbens by microdialysis. *Alcohol Clin Exp Res*. 1998;22:367-374.
75. Gonzales RA, Weiss F. Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. *J Neurosci*. 1998;18:10663-10671.
76. Nurmi M, Sinclair JD, Kiianmaa K. Dopamine release during ethanol drinking in AA rats. *Alcohol Clin Exp Res*. 1998;22:1628-1633.
77. Yoshimoto K, Ueda S, Kato B, et al. Alcohol enhances characteristic releases of dopamine and serotonin in the central nucleus of the amygdala. *Neurochem Int*. 2000;37:369-376.
78. Phillips TJ, Brown KJ, Burkhardt-Kasch S, et al. Alcohol preference and sensitivity are markedly reduced in mice lacking dopamine D2 receptors. *Nat Neurosci*. 1998;1:610-615.
79. Budygin EA, Phillips PE, Robinson DL, et al. Effect of acute ethanol on striatal dopamine neurotransmission in ambulatory rats. *J Pharmacol Exp Ther*. 2001;297:27-34.
80. Olive MF, Nannini MA, Ou CJ, et al. Effects of acuteacamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release. *Eur J Pharmacol*. 2002;437:55-61.

81. Sharp T, Bramwell SR, Clark D, et al. In vivo measurement of extracellular 5-hydroxytryptamine in hippocampus of the anaesthetized rat using microdialysis: changes in relation to 5-hydroxytryptaminergic neuronal activity. *J Neurochem*. 1989;53:234-240.
82. Sprouse JS, Bradberry CW, Roth RH, et al. 3,4-Methylenedioxymethamphetamine-induced release of serotonin and inhibition of dorsal raphe cell firing: potentiation by L-tryptophan. *Eur J Pharmacol*. 1990;178:313-320.
83. Ferre S, Artigas F. Clozapine decreases serotonin extracellular levels in the nucleus accumbens by a dopamine receptor-independent mechanism. *Neurosci Lett*. 1995;187:61-64.
84. Dailey JW, Reith ME, Steidley KR, et al. Carbamazepine-induced release of serotonin from rat hippocampus in vitro. *Epilepsia*. 1998;39:1054-1063.
85. Voigt JP, Kienzle F, Sohr R, et al. Feeding and 8-OH-DPAT-related release of serotonin in the rat lateral hypothalamus. *Pharmacol Biochem Behav*. 2000;65:183-189.
86. Hayashi M, Nakai T, Bandoh T, et al. Acute effect of simultaneous administration of tryptophan and ethanol on serotonin metabolites in the locus coeruleus in rats. *Eur J Pharmacol*. 2003;462:61-66.
87. Luparini MR, Garrone B, Pazzagli M, et al. A cortical GABA-5HT interaction in the mechanism of action of the antidepressant trazodone. *Prog Neuropsychopharmacol Biol Psychiatry*. 2004;28:1117-1127.
88. Celik T, Goren MZ, Cinar K, et al. Fatigue of cholestasis and the serotonergic neurotransmitter system in the rat. *Hepatology*. 2005;41:731-737.
89. Owen JC, Whitton PS. Effects of amantadine and budipine on antidepressant drug-evoked changes in extracellular 5-HT in the frontal cortex of freely moving rats. *Br J Pharmacol*. 2005;145:587-592.
90. Hernandez L, Lee F, Hoebel BG. Simultaneous microdialysis and amphetamine infusion in the nucleus accumbens and striatum of freely moving rats: increase in extracellular dopamine and serotonin. *Brain Res Bull*. 1987;19:623-628.
91. Stenfors C, Ross SB. Changes in extracellular 5-HIAA concentrations as measured by in vivo microdialysis technique in relation to changes in 5-HT release. *Psychopharmacology (Berl)*. 2004;172:119-128.
92. Rollema H, Clarke T, Sprouse JS, et al. Combined administration of a 5-hydroxytryptamine (5-HT)1D antagonist and a 5-HT reuptake inhibitor synergistically increases 5-HT release in guinea pig hypothalamus in vivo. *J Neurochem*. 1996;67:2204-2207.
93. Stenfors C, Magnusson T, Larsson LG, et al. Synergism between 5-HT1B/1D and 5-HT1A receptor antagonists on turnover and release of 5-HT in guinea-pig brain in vivo. *Naunyn Schmiedeberg Arch Pharmacol*. 1999;359:110-116.
94. Segovia J, Tossman U, Herrera-Marschitz M, et al. Gamma-aminobutyric acid release in the globus pallidus in vivo after a 6-hydroxydopamine lesion in the substantia nigra of the rat. *Neurosci Lett*. 1986;70:364-368.
95. Butcher SP, Sandberg M, Hagberg H, et al. Cellular origins of endogenous amino acids released into the extracellular fluid of the rat striatum during severe insulin-induced hypoglycemia. *J Neurochem*. 1987;48:722-728.
96. Wang J, Shen LL, Cao YX, et al. Effects of electroacupuncture on pressor response to angiotensin-(1-7) by amino acid release in the rostral ventrolateral medulla. *Acupunct Electrother Res*. 2003;28:25-34.
97. Touchon JC, Holmer HK, Moore C, et al. Apomorphine-induced alterations in striatal and substantia nigra pars reticulata glutamate following unilateral loss of striatal dopamine. *Exp Neurol*. 2005;193:131-140.
98. Ahmad S, Fowler LJ, Whitton PS. Effects of acute and chronic lamotrigine treatment on basal and stimulated extracellular amino acids in the hippocampus of freely moving rats. *Brain Res*. 2004;1029:41-47.
99. Quertemont E, de Neuville J, De Witte P. Changes in the amygdala amino acid microdialysate after conditioning with a cue associated with ethanol. *Psychopharmacology (Berl)*. 1998;139:71-78.
100. Dahchour A, De Witte P. Ethanol and amino acids in the central nervous system: assessment of the pharmacological actions of acamprosate. *Prog Neurobiol*. 2000;60:343-362.
101. Dahchour A, Quertemont E, De Witte P. Acute ethanol increases taurine but neither glutamate nor GABA in the nucleus accumbens of male rats: a microdialysis study. *Alcohol Alcohol*. 1994;29:485-487.
102. Dahchour A, Quertemont E, De Witte P. Taurine increases in the nucleus accumbens microdialysate after acute ethanol administration to naive and chronically alcoholised rats. *Brain Res*. 1996;735:9-19.
103. Quertemont E, Goffaux V, Vlamincx AM, et al. Oral taurine supplementation modulates ethanol-conditioned stimulus preference. *Alcohol*. 1998;16:201-206.
104. Quertemont E, Lallemand F, Colombo G, et al. Taurine and ethanol preference: a microdialysis study using Sardinian alcohol-preferring and non-preferring rats. *Eur Neuropsychopharmacol*. 2000;10:377-383.
105. Katner SN, Weiss F. Neurochemical characteristics associated with ethanol preference in selected alcohol-preferring and -nonpreferring rats: a quantitative microdialysis study. *Alcohol Clin Exp Res*. 2001;25:198-205.
106. Piepponen TP, Kiianmaa K, Ahtee L. Effects of ethanol on the accumbal output of dopamine, GABA and glutamate in alcohol-tolerant and alcohol-nontolerant rats. *Pharmacol Biochem Behav*. 2002;74:21-30.
107. Quertemont E, Linotte S, de Witte P. Differential taurine responsiveness to ethanol in high- and low-alcohol sensitive rats: a brain microdialysis study. *Eur J Pharmacol*. 2002;444:143-150.
108. Dahchour A, De Witte P. Effect of repeated ethanol withdrawal on glutamate microdialysate in the hippocampus. *Alcohol Clin Exp Res*. 1999;23:1698-1703.
109. Dahchour A, De Witte P, Bolo N, et al. Central effects of acamprosate: part I. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats. *Psychiatry Res*. 1998;82:107-114.
110. Dahchour A, De Witte P. Taurine blocks the glutamate increase in the nucleus accumbens microdialysate of ethanol-dependent rats. *Pharmacol Biochem Behav*. 2000;65:345-350.
111. Dahchour A, De Witte P. Excitatory and inhibitory amino acid changes during repeated episodes of ethanol withdrawal: an in vivo microdialysis study. *Eur J Pharmacol*. 2003;459:171-178.
112. Dahchour A, De Witte P. Acamprosate decreases the hypermotility during repeated ethanol withdrawal. *Alcohol*. 1999;18:77-81.
113. Dahchour A, De Witte P. Effects of acamprosate on excitatory amino acids during multiple ethanol withdrawal periods. *Alcohol Clin Exp Res*. 2003;27:465-470.
114. Rooyackers O. Microdialysis to investigate tissue amino acid kinetics. *Curr Opin Clin Nutr Metab Care*. 2005;8:77-82.
115. Timmerman W, Westerink BH. Brain microdialysis of GABA and glutamate: what does it signify? *Synapse*. 1997;27:242-261.

116. Baker DA, McFarland K, Lake RW, et al. Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. *Nat Neurosci*. 2003;6:743-749.
117. Lada MW, Vickroy TW, Kennedy RT. High temporal resolution monitoring of glutamate and aspartate in vivo using microdialysis on-line with capillary electrophoresis with laser-induced fluorescence detection. *Anal Chem*. 1997;69:4560-4565.
118. Lada MW, Vickroy TW, Kennedy RT. Evidence for neuronal origin and metabotropic receptor-mediated regulation of extracellular glutamate and aspartate in rat striatum in vivo following electrical stimulation of the prefrontal cortex. *J Neurochem*. 1998;70:617-625.
119. Rooyackers O, Myrenfors P, Nygren J, et al. Insulin stimulated glucose disposal in peripheral tissues studied with microdialysis and stable isotope tracers. *Clin Nutr*. 2004;23:743-752.
120. Horn TF, Engelmann M. In vivo microdialysis for nonapeptides in rat brain—a practical guide. *Methods*. 2001;23:41-53.
121. Lindefors N, Brodin E, Ungerstedt U. Amphetamine facilitates the in vivo release of neurokinin A in the nucleus accumbens of the rat. *Eur J Pharmacol*. 1989;160:417-420.
122. Lindefors N, Brodin E, Ungerstedt U. Subchronic haloperidol treatment decreases the in vivo release of tachykinins in rat substantia nigra. *Eur J Pharmacol*. 1989;161:95-98.
123. Gruber SH, Mathe AA. Effects of typical and atypical antipsychotics on neuropeptide Y in rat brain tissue and microdialysates from ventral striatum. *J Neurosci Res*. 2000;61:458-463.
124. Landgraf R, Neumann I, Holsboer F, et al. Interleukin-1 beta stimulates both central and peripheral release of vasopressin and oxytocin in the rat. *Eur J Neurosci*. 1995;7:592-598.
125. Vasilaki A, Papasava D, Hoyer D, et al. The somatostatin receptor (sst1) modulates the release of somatostatin in the nucleus accumbens of the rat. *Neuropharmacology*. 2004;47:612-618.
126. Olive MF, Koenig HN, Nannini MA, Hodge CW. Stimulation of endorphin neurotransmission in the nucleus accumbens by ethanol, cocaine, and amphetamine. *J Neurosci*. 2001;21:RC184.
127. Roth-Deri I, Schindler CJ, Yadid G. A critical role for beta-endorphin in cocaine-seeking behavior. *Neuroreport*. 2004;15:519-521.
128. Herz A. Endogenous opioid systems and alcohol addiction. *Psychopharmacology (Berl)*. 1997;129:99-111.
129. Solinas M, Zangen A, Thiriet N, et al. Beta-endorphin elevations in the ventral tegmental area regulate the discriminative effects of delta-9-tetrahydrocannabinol. *Eur J Neurosci*. 2004;19:3183-3192.
130. Beinfeld MC, Connolly KJ, Pierce RC. Cocaine treatment increases extracellular cholecystokinin (CCK) in the nucleus accumbens shell of awake, freely moving rats, an effect that is enhanced in rats that are behaviorally sensitized to cocaine. *J Neurochem*. 2002;81:1021-1027.
131. Emmett MR, Andren PE, Caprioli RM. Specific molecular mass detection of endogenously released neuropeptides using in vivo microdialysis/mass spectrometry. *J Neurosci Methods*. 1995;62:141-147.
132. Haskins WE, Wang Z, Watson CJ, et al. Capillary LC-MS2 at the attomole level for monitoring and discovering endogenous peptides in microdialysis samples collected in vivo. *Anal Chem*. 2001;73:5005-5014.
133. Sijbesma H, Schipper J, Molewijk HE, et al. 8-hydroxy-2-(di-N-propylamino)tetralin increases the activity of adenylate cyclase in the hippocampus of freely-moving rats. *Neuropharmacology*. 1991;30:967-975.
134. Mi Z, Herzer WA, Zhang Y, Jackson EK. 3-isobutyl-1-methylxanthine decreases renal cortical interstitial levels of adenosine and inosine. *Life Sci*. 1994;54:277-282.
135. Wu HQ, Fuxe K, Schwarcz R. Neuronal A1 receptors mediate increase in extracellular kynurenic acid after local intrastriatal adenosine infusion. *J Neurochem*. 2004;90:621-628.
136. Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. *Nat Neurosci*. 1999;2:358-363.
137. Yamamoto M, Koshimura K, Sohmiya M, et al. Effect of erythropoietin on nitric oxide production in the rat hippocampus using in vivo brain microdialysis. *Neuroscience*. 2004;128:163-168.
138. Hara S, Mukai T, Kurosaki K, et al. Characterization of suppression of nitric oxide production by carbon monoxide poisoning in the striatum of free-moving rats, as determined by in vivo brain microdialysis. *Brain Res*. 2003;979:27-36.
139. Yang WP, Oshida Y, Wu W, et al. Effect of daily voluntary running on in vivo insulin action in rat skeletal muscle and adipose tissue as determined by the microdialysis technique. *Int J Sports Med*. 1995;16:99-104.
140. Rosdahl H, Hamrin K, Ungerstedt U, et al. A microdialysis method for the in situ investigation of the action of large peptide molecules in human skeletal muscle: detection of local metabolic effects of insulin. *Int J Biol Macromol*. 2000;28:69-73.
141. Canal CE, McNay EC, Gold PE. Increases in extracellular fluid glucose levels in the rat hippocampus following an anesthetic dose of pentobarbital or ketamine-xylazine: an in vivo microdialysis study. *Physiol Behav*. 2005;84:245-250.
142. Gardenfors F, Nilsson A, Ungerstedt U, et al. Adverse biochemical and physiological effects of prostacyclin in experimental brain oedema. *Acta Anaesthesiol Scand*. 2004;48:1316-1321.
143. Hamrin K, Henriksson J. Local effect of vanadate on interstitial glucose and lactate concentrations in human skeletal muscle. *Life Sci*. 2005;76:2329-2338.
144. Djurhuus CB, Gravholt CH, Nielsen S, Pedersen SB, Moller N, Schmitz O. Additive effects of cortisol and growth hormone on regional and systemic lipolysis in humans. *Am J Physiol Endocrinol Metab*. 2004;286:E488-E494.
145. Richterova B, Stich V, Moro C, et al. Effect of endurance training on adrenergic control of lipolysis in adipose tissue of obese women. *J Clin Endocrinol Metab*. 2004;89:1325-1331.
146. Djurhuus CB, Gravholt CH, Nielsen S, et al. Effects of cortisol on lipolysis and regional interstitial glycerol levels in humans. *Am J Physiol Endocrinol Metab*. 2002;283:E172-E177.
147. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med*. 1993;329:977-986.
148. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet*. 1998;352:837-853.
149. Nakahara D, Nakamura M, Iigo M, et al. Bimodal circadian secretion of melatonin from the pineal gland in a living CBA mouse. *Proc Natl Acad Sci USA*. 2003;100:9584-9589.

150. Perreau-Lenz S, Kalsbeek A, Van Der Vliet J, et al. In vivo evidence for a controlled offset of melatonin synthesis at dawn by the suprachiasmatic nucleus in the rat. *Neuroscience*. 2005;130:797-803.
151. Hoffner L, Nielsen JJ, Langberg H, et al. Exercise but not prostanoids enhance levels of vascular endothelial growth factor and other proliferative agents in human skeletal muscle interstitium. *J Physiol*. 2003;550:217-225.
152. Garvin S, Dabrosin C. Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo. *Cancer Res*. 2003;63:8742-8748.
153. Sandeep TC, Andrew R, Homer NZ, et al. Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. *Diabetes*. 2005;54:872-879.
154. Pau KY, Lee CJ, Cowles A, et al. Possible involvement of norepinephrine transporter activity in the pulsatility of hypothalamic gonadotropin-releasing hormone release: influence of the gonad. *J Neuroendocrinol*. 1998;10:21-29.
155. Lindley SE, Bengoechea TG, Wong DL, et al. Mesotelencephalic dopamine neurochemical responses to glucocorticoid administration and adrenalectomy in Fischer 344 and Lewis rats. *Brain Res*. 2002;958:414-422.